STOCK TITAN

Rainier Acquisition Corporation Announces Separation of Its Class A Ordinary Shares and Warrants on Nasdaq, Commencing September 14, 2026

Rainier’s SPAC units become separately tradable into Class A shares and warrants as its $86.25 million IPO units start to decouple on Nasdaq.

(Neutral)
Tags

Rainier Acquisition Corporation (RNAQ) will allow holders of its Nasdaq-listed units to separately trade the embedded Class A ordinary shares and warrants starting September 14, 2026. Each unit, which has traded under the symbol “RNAQU” since August 27, 2026, consists of one Class A ordinary share and one-quarter of one redeemable warrant. No fractional warrants are issued on separation, and only whole warrants will trade and be exercisable.

The separated Class A ordinary shares and whole warrants are expected to begin trading on Nasdaq on September 15, 2026 under the symbols “RNAQ” and “RNAQW,” respectively, while unsplit units will continue under “RNAQU.” Each whole warrant entitles its holder to purchase one Class A ordinary share at an exercise price of $11.50 per share, subject to adjustments. Rainier’s initial public offering, including full exercise of the underwriter’s over-allotment option, comprised 8,625,000 units and generated gross proceeds of $86,250,000, with $10.00 per unit placed into a trust account.

Loading...
Loading translation...

Positive

  • 8,625,000 units sold in the IPO, including full over-allotment
  • IPO generated $86,250,000 in gross proceeds
  • $10.00 per unit, totaling $86,250,000, deposited into a trust account
  • Units become separable into Class A shares and warrants starting September 14, 2026
  • Separated securities obtain distinct Nasdaq symbols: RNAQ for shares and RNAQW for warrants

Negative

  • None.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

The Class A ordinary shares will trade under the symbol “RNAQ” and the warrants under the symbol “RNAQW” on The Nasdaq Capital Market, while units that are not separated will continue to trade under the symbol “RNAQU.”

NEW YORK, NY, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Rainier Acquisition Corporation (Nasdaq: RNAQU) (the “Company”) announced today that, commencing September 14, 2026, holders of the units sold in its initial public offering (the “Units”) may elect to separately trade the Class A ordinary shares and warrants included in the Units. Each Unit consists of one Class A ordinary share and one-quarter of one redeemable warrant. No fractional warrants will be issued upon separation of the Units, and only whole warrants will trade. Each whole warrant entitles the holder thereof to purchase one Class A ordinary share at a price of $11.50 per share, subject to certain adjustments. Only whole warrants are exercisable.

The Class A ordinary shares and warrants that are separated will begin trading on The Nasdaq Capital Market (“Nasdaq”) on September 15, 2026 under the symbols “RNAQ” and “RNAQW,” respectively. Units that are not separated will continue to trade on Nasdaq under the symbol “RNAQU.” Holders of Units will need to have their brokers contact Continental Stock Transfer & Trust Company, the Company’s transfer agent, in order to separate the Units into Class A ordinary shares and warrants.

The Units began trading on Nasdaq on August 27, 2026. The Company’s initial public offering, including the full exercise of the underwriter’s over-allotment option, totaled 8,625,000 Units and generated gross proceeds of $86,250,000, before underwriting discounts and offering expenses, and an aggregate of $86,250,000 ($10.00 per Unit) was placed in the Company’s trust account. Chardan Capital Markets LLC (“Chardan”) acted as the sole book-running manager for the offering.

About Rainier Acquisition Corporation

Rainier Acquisition Corporation (Nasdaq: RNAQU, RNAQ, RNAQW) is a special purpose acquisition company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus its search on the global life sciences industries, including therapeutics, diagnostics, genomics, precision medicine, life science tools, research services, biomanufacturing, and related subsectors, although its efforts to identify a prospective target business will not be limited to any particular industry or geographical region. The Company’s management team is led by Gbola Amusa, MD, CFA, Chief Executive Officer, and Guy Barudin, Chief Financial Officer. The Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) are available at www.sec.gov.

The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from Chardan, 1 Pennsylvania Plaza, Suite 4800, New York, New York 10119, or by email at prospectus@chardan.com.

A registration statement relating to these securities was declared effective by the SEC on August 26, 2026. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any State or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such State or jurisdiction.

Cautionary Note Concerning Forward-Looking Statements

This press release includes forward-looking statements that involve risks and uncertainties, including with respect to the timing of separate trading and the Company’s search for an initial business combination. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ from the forward-looking statements. The Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. Forward-looking statements are subject to numerous conditions, many of which are beyond the control of the Company, including those set forth in the Risk Factors section of the Company’s registration statement and related prospectus for the Company’s initial public offering filed with the SEC. Copies of these documents are available on the SEC’s website, at www.sec.gov. The Company undertakes no obligation to update these statements for revisions or changes after the date of this release, except as required by law.

Contact:
Rainier Acquisition Corporation
Gbola Amusa, MD, CFA, Chief Executive Officer
1 Pennsylvania Plaza, Suite 4800
New York, NY 10119
Tel.: (646) 465-9000
gamusa@rainier-acq.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When can Rainier Acquisition Corporation unit holders begin separating their units into Class A ordinary shares and warrants?

Holders of units sold in the initial public offering may elect to separately trade the Class A ordinary shares and warrants included in the units commencing September 14, 2026. Units that are not separated will continue to trade on Nasdaq under the symbol “RNAQU.”

What are the Nasdaq trading symbols and start dates for Rainier’s separated Class A ordinary shares and warrants?

The separated Class A ordinary shares are expected to begin trading on Nasdaq on September 15, 2026 under the symbol “RNAQ,” and the separated warrants are expected to begin trading the same day under the symbol “RNAQW.”

How can holders of RNAQU units complete the separation into Class A shares and warrants?

Holders of units must have their brokers contact Continental Stock Transfer & Trust Company, Rainier Acquisition Corporation’s transfer agent, to separate the units into individual Class A ordinary shares and warrants.

What are the key terms of Rainier Acquisition Corporation’s warrants?

Each unit includes one-quarter of one redeemable warrant. No fractional warrants are issued upon separation, and only whole warrants will trade and be exercisable. Each whole warrant entitles its holder to purchase one Class A ordinary share at an exercise price of $11.50 per share, subject to certain adjustments.

Keep reading